摘要
目的观察治瘊颗粒联合胸腺肽治疗扁平疣的临床疗效。方法选取2012年9月—2014年9月在我科治疗的扁平疣患者98例,联合治疗组50例患者采用治瘊颗粒联合胸腺肽治疗方案,对照组48例患者单用胸腺肽治疗,观察治疗前后外周血T淋巴细胞亚群的比例变化和治疗后临床疗效。结果联合治疗组痊愈率、总有效率(78.00%,94.00%)显著大于对照组(58.33%,79.17%),好转率(2.00%)低于对照组(20.83%),差异有统计学意义(P<0.05);余指标差异无统计学意义(P>0.05);2组治疗前各淋巴细胞亚群比较,差异无统计学意义(P>0.05);联合治疗组治疗后CD4^+、CD8^+、CD4^+/CD8^+与治疗前差异有统计学意义,对照组治疗后CD4^+、CD8^+、CD4^+/CD8^+与治疗前差异有统计学意义(P<0.05);联合治疗组治疗后CD4^+、CD4^+/CD8^+显著大于对照组(P<0.05)。结论治瘊颗粒与胸腺肽联合治疗扁平疣的效果较单用胸腺肽更优,CD4^+、CD4^+/CD8^+水平的升高也更显著。
Objective In order to observe clinical effects of Zhihou granular formulation combined with thymosin in the treatment of verruca plana. Methods Ninty-eight patients with verruca plana treated in our hospital from September 2012 to September 2014 were chosen. Fifty patients in the combined treatment group were treated with Zhihou granular formulation combined with thymosin, while 48 patients in the control group were treated with thymosin. The changes of T lymphocyte subsets in peripheral blood were observed as well as the clinical effect. Results The curative rate and total effective rates （78%, 94%） in the combined treatment group were significantly higher than those in the control group （58.33%, 79.17%）, and the improvement （2%） was significantly lower than that in the control group （20.83%, P〈0.05）. The other indicators and the comparison of lymphocyte subsets in the two groups before treatment were not significantly changed （P〉0.05）. CD4^＋, CD8^＋, CD4^＋/CD8^＋ of combined treatment group and control group were significantly changed after treatment. CD4^＋, CD4^＋/CD8^＋ of combined treatment group were significantly higher than the control group. Conclusion Zhihou granular formulation combined with thymosin in treating verruca plana is more effective than single-use of thymosin, and it can significantly promote CD4^＋, CD4^＋/CD8^＋ secretion.
出处
《中国中西医结合皮肤性病学杂志》
CAS
2016年第3期158-160,共3页
Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
关键词
扁平疣
治瘊颗粒
胸腺肽
Verruca plana
Zhihou granular formulation
Thymosin
